All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Performance comparison

Mecasermin (Increlex) vs MK-677 (Ibutamoren)

An educational, source-based comparison of Mecasermin (Increlex) and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.

IGF-1 · Endocrine
Mecasermin (Increlex)

Recombinant human IGF-1 for severe primary IGF-1 deficiency.

Mechanism

Recombinant human insulin-like growth factor-1 (rhIGF-1) that binds IGF-1 receptors to promote linear growth in children with severe primary IGF-1 deficiency or GH gene deletion with anti-GH antibodies.

Research areas
  • Severe primary IGF-1 deficiency
  • Growth failure with GH gene deletion and neutralizing GH antibodies
Considerations
  • FDA-approved.
  • Hypoglycemia — must be taken with food.
  • Tonsillar hypertrophy, intracranial hypertension reported.
Full Mecasermin (Increlex) profile →
Growth Hormone Axis · Small Molecule
MK-677 (Ibutamoren)

Orally bioavailable non-peptide ghrelin mimetic.

Mechanism

Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.

Research areas
  • GH/IGF-1 elevation in adults
  • Lean mass and bone density in elderly
  • Sleep quality (slow-wave sleep)
Considerations
  • Not FDA-approved.
  • Insulin resistance and fluid retention reported.
  • Banned by WADA.
Full MK-677 (Ibutamoren) profile →

Mecasermin (Increlex) vs MK-677 (Ibutamoren) — Key differences

  • Class: Mecasermin (Increlex) is classified as IGF-1 · Endocrine, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
  • Primary research focus: Mecasermin (Increlex)severe primary igf-1 deficiency; MK-677 (Ibutamoren)gh/igf-1 elevation in adults.
  • Tag: FDA-Approved · Endocrine vs Growth hormone · Oral.

Related comparisons